Bonesupport Holding AB (publ) (0RQO.L)
- Previous Close
253.60 - Open
250.80 - Bid --
- Ask --
- Day's Range
245.00 - 252.20 - 52 Week Range
74.65 - 252.20 - Volume
17,614 - Avg. Volume
16,823 - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.65
- PE Ratio (TTM)
-- - EPS (TTM)
-1.27 - Earnings Date Jul 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Bonesupport Holding AB (publ), an orthobiologics company, develops and sells injectable bio-ceramic bone graft substitutes in Europe, North America, and internationally. The company provides CERAMENT Bone Void Filler, an injectable ceramic bone graft substitute that remodels to host bone; CERAMENT G, an injectable ceramic bone graft substitute that remodels to host bone and elutes Gentamicin during the critical first 30 days of bone healing, as well as treats and prevents bone infection; CERAMENT V, an injectable ceramic bone graft substitute that remodels to host bone and elutes Vancomycin during the critical first 30 days of bone healing, as well as treats and prevents bone infection. It also offers CERAMENT Bead Tray, an adjunctive local delivery option for surgeons for targeted delivery to osseous defects and for dead space management. In addition, the company develops preclinical product candidates to promote bone regrowth focusing on trauma, revision arthroplasty, chronic osteomyelitis, and foot and ankle surgery. Bonesupport Holding AB (publ) was founded in 1999 and is headquartered in Lund, Sweden.
www.bonesupport.com140
Full Time Employees
December 31
Fiscal Year Ends
--
Sector
--
Industry
Recent News: 0RQO.L
View MorePerformance Overview: 0RQO.L
Trailing total returns as of 6/3/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 0RQO.L
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 0RQO.L
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
12.26%
Return on Assets (ttm)
11.16%
Return on Equity (ttm)
18.60%
Revenue (ttm)
997.85M
Net Income Avi to Common (ttm)
122.34M
Diluted EPS (ttm)
-1.27
Balance Sheet and Cash Flow
Total Cash (mrq)
267.14M
Total Debt/Equity (mrq)
1.71%
Levered Free Cash Flow (ttm)
-2.98M